Theravance Biopharma, Inc.
TBPH
$13.91
$0.251.83%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 503.82% | 12.55% | -22.28% | 23.18% | -41.71% |
| Total Depreciation and Amortization | -2.18% | -6.51% | -5.33% | 0.00% | 1.63% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -278.86% | 548.03% | -111.72% | -20.07% | 57.56% |
| Change in Net Operating Assets | 203.82% | 274.00% | 4,160.53% | -112.70% | -34.63% |
| Cash from Operations | 383.45% | 4,871.51% | 82.64% | -17.69% | -332.00% |
| Capital Expenditure | -- | -- | -1,166.67% | 58.33% | 60.44% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -218.26% | 92.95% | 191.33% | -480.43% | -117.50% |
| Cash from Investing | -218.37% | 95.28% | 190.15% | -474.03% | -117.80% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -100.00% | -87.73% | 552.00% | -94.03% | -- |
| Repurchase of Common Stock | 42.45% | -65.53% | -33.00% | 14.25% | 73.02% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 41.10% | -133.97% | 1.88% | -745.45% | 97.44% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 135.27% | 405.01% | 162.78% | -206.64% | -152.41% |